An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice. Issue 3 (28th December 2017)

• Record Type: Journal Article
• Authors: Ellison, Gillian; Ahdesmäki, Miika; Luke, Sally; Waring, Paul M.; Wallace, Andrew; Wright, Ronnie; Röthlisberger, Benno; Ludin, Katja; Merkelbach‐Bruse, Sabine; Heydt, Carina; Ligtenberg, Marjolijn J.L.; Mensenkamp, Arjen R.; de Castro, David Gonzalez; Jones, Thomas; Vivancos, Ana; Kondrashova, Olga; Pauwels, Patrick; Weyn, Christine; Hahnen, Eric; Hauke, Jan; Soong, Richie; Lai, Zhongwu; Dougherty, Brian; Carr, T. Hedley; Johnson, Justin; Mills, John; Barrett, J. Carl
• Is Part Of: Human mutation. Volume 39:Issue 3(2018)
• Page Start: 394
• Page End: 405
• Publication Date: 2017-12-28
• Subjects: diagnostic -- FFPE -- NGS -- PARP -- tBRCA; Human chromosome abnormalities -- Periodicals; Mutation (Biology) -- Periodicals; 616.04205
• DOI: 10.1002/humu.23375
• Languages: English
• ISSNs: 1059-7794

Abstract

Abstract: Ovarian cancer patients with germline or somatic pathogenic variants benefit from treatment with poly ADP ribose polymerase (PARP) inhibitors. Tumor BRCA1/2 testing is more challenging than germline testing as the majority of samples are formalin‐fixed paraffin embedded (FFPE), the tumor genome is complex, and the allelic fraction of somatic variants can be low. We collaborated with 10 laboratories testing BRCA1/2 in tumors to compare different approaches to identify clinically important variants within FFPE tumor DNA samples. This was not a proficiency study but an inter‐laboratory comparison to identify common issues. Each laboratory received the same tumor DNA samples ranging in genotype, quantity, quality, and variant allele frequency (VAF). Each laboratory performed their preferred next‐generation sequencing method to report on the variants. No false positive results were reported in this small study and the majority of methods detected the low VAF variants. A number of variants were not detected due to the bioinformatics analysis, variant classification, or insufficient DNA. The use of hybridization capture or short amplicon methods are recommended based on a bioinformatic assessment of the data. The study highlights the importance of establishing standards and standardization for t BRCA testing particularly when the test results dictate clinical decisions regarding life extending therapies. Abstract : Ovarian cancer patients with germline or somatic pathogenic variants in the BRCA genes benefit from treatment with PARP inhibitors. Tumour BRCA1/2 testing is challenging as the majority of samples are FFPE, the tumour genome is complex and the allelic fraction of somatic variant can be low. This study reports intriguing results from ten independent tBRCA testing laboratories and highlights the importance of establishing standards and standardization particularly when the test results dictate clinical decisions regarding life extending therapies.